Intech Investment Management LLC Buys 48,622 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Intech Investment Management LLC increased its Gilead Sciences stake by 19.9% in the fourth quarter, buying 48,622 additional shares and bringing its total holding to 293,214 shares worth about $36 million.
• Wall Street remains broadly positive on Gilead, with 25 analysts rating it a Buy and four a Hold; the stock’s average rating is Moderate Buy with an average target price of $156.93.
• Gilead reported better-than-expected quarterly results, posting EPS of $2.03 versus the $1.91 consensus and revenue of $6.96 billion, while also declaring a quarterly dividend of $0.82 per share.

Intech Investment Management LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 19.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 293,214 shares of the biopharmaceutical company's stock after buying an additional 48,622 shares during the period. Intech Investment Management LLC's holdings in Gilead Sciences were worth $35,989,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Paulson Wealth Management Inc. increased its position in Gilead Sciences by 1.8% during the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company's stock valued at $477,000 after buying an additional 67 shares in the last quarter. Alpha Cubed Investments LLC increased its holdings in shares of Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company's stock worth $812,000 after purchasing an additional 75 shares in the last quarter. Personal CFO Solutions LLC increased its holdings in shares of Gilead Sciences by 1.7% in the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company's stock worth $561,000 after purchasing an additional 76 shares in the last quarter. Moss Adams Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 1.7% in the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company's stock worth $546,000 after purchasing an additional 76 shares in the last quarter. Finally, Valued Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 12.5% in the 4th quarter. Valued Wealth Advisors LLC now owns 711 shares of the biopharmaceutical company's stock worth $87,000 after purchasing an additional 79 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of research analyst reports. Royal Bank Of Canada reduced their target price on Gilead Sciences from $123.00 to $122.00 and set a "sector perform" rating for the company in a report on Friday, May 8th. TD Cowen lifted their target price on Gilead Sciences from $145.00 to $160.00 and gave the stock a "buy" rating in a report on Wednesday, February 11th. Cantor Fitzgerald reduced their target price on Gilead Sciences from $155.00 to $115.00 and set an "overweight" rating for the company in a report on Friday, April 10th. Weiss Ratings raised Gilead Sciences from a "buy (b-)" rating to a "buy (b)" rating in a report on Monday, May 11th. Finally, Bank of America set a $162.00 target price on Gilead Sciences and gave the stock a "buy" rating in a report on Wednesday, February 11th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $156.93.

Gilead Sciences Stock Performance

GILD stock opened at $136.22 on Friday. The company has a market cap of $169.13 billion, a P/E ratio of 18.56 and a beta of 0.31. Gilead Sciences, Inc. has a 1 year low of $104.46 and a 1 year high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The stock's fifty day moving average price is $135.43 and its 200-day moving average price is $134.08.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company's revenue for the quarter was up 4.4% on a year-over-year basis. During the same period last year, the business posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050--0.650 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Monday, June 15th. Gilead Sciences's dividend payout ratio (DPR) is 44.69%.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction on Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the transaction, the insider directly owned 125,779 shares in the company, valued at $16,513,524.91. This trade represents a 18.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total value of $1,291,600.00. Following the completion of the transaction, the chief executive officer owned 632,567 shares in the company, valued at approximately $81,702,353.72. This trade represents a 1.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 53,000 shares of company stock worth $7,075,670 in the last ninety days. Insiders own 0.30% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.